A compilation of news articles in the field of gynecologic oncology and recent scientific studies
Clinical research must include underrepresented groups, NIH experts say
December 28, 2017: NIH News – “To realize the promise of personalized medicine, new research studies must include segments of the population often overlooked in clinical research: children, older adults, pregnant women, and individuals with physical, intellectual, and developmental disabilities.” Read more.
Targeting tumor vasculature in ovarian cancer
December 27, 2017: Onc Live – In an interview with OncLive during the 35th annual CFS®, Dr. Robert Coleman discussed targeting tumor vasculature and angiogenesis in ovarian cancer. Read the interview.
Dr. Lederman on systemic treatment for rare gynecologic tumors
December 27, 2017: Onc Live – Rare tumors are the hardest ones to treat because less is understood about their biology and the current drugs are not as active in these tumors, explains Ledermann. In order to understand the management of rare epithelial tumors, global collaborative studies are needed. See the video.
Ovarian cancer trial: disappointing results of paclitaxel with/without pazopanib
December 26, 2017: Medical Research.com interview with Debra Richardson, MD regarding national, randomized, double-blind, placebo controlled phase 2b trial of weekly paclitaxel with or without pazopanib for the treatment of recurrent ovarian cancer. Read the interview. See another article on the topic from Oncology Nurse Advisor.
Nanoparticle delivery of cancer drugs effective in endometrial cancer
December 25, 2017: Specialty Pharmacy Times – “Delivering a combination of cancer drugs via a targeted nanoparticle may provide a more potent treatment against a deadly form of endometrial cancer, according to a study published by Nature Nanotechnology. In the study, chemotherapy and a drug that combats drug-resistant cells were loaded into nanoparticles in an attempt to create a highly-effective approach to treating cancer.” Read more. See another article on this topic from Medical News Today.
Prevention is better than cure
December 25, 2017: Tribune India – CN Purandare, Alka Kriplani & Neerja Bhatla discuss the state of cervical cancer in India. Read more.
Future of Immunotherapy in ovarian cancer to include combinations
December 22, 2017: Onc Live – Dr. Bradley Monk discusses clinical trials evaluating checkpoint blockade in combination regimens and the potential of immunotherapy in ovarian cancer. Read more
Genomic profiling tests cleared by FDA can help guide cancer treatment, clinical trial enrollment
December 21, 2017: NCI Cancer Currents Blog: “Over the past month, the Food and Drug Administration (FDA) has approved two tests to identify genetic alterations in tumors.” Read more.
ACOG backs ‘cascade testing’ for cancer related mutations.
December 21, 2017: MedPage Today: Ob/gyns should provide genetic counseling and testing for blood relatives of patients with known cancer mutations, otherwise known as “cascade testing,” the American College of Obstetricians and Gynecologists (ACOG) said. Read more.
Study finds optimal time for getting postoperative chemotherapy for ovarian cancer
December 20, 2017: Korea Biomedical Review: “New research says ovarian cancer patients should get postoperative adjuvant chemotherapy (POAC) earlier than later – proving those who got POAC within 42 days after completing neoadjuvant chemotherapy lived longer.” Read more. Read an additional article on the subject from Cure Today.
Histology and cytopathology capacity in the public health sector in Kenya
December, 2017: Journal of Global Oncology – Histology and cytopathology services are necessary for cancer diagnosis and treatment. However, the current capacity of Kenya’s pathology laboratories is unknown. A national survey was conducted among public sector pathology laboratories to assess their capacity to perform histology, fine-needle aspiration, and bone marrow aspiration.” Read the study.
Multinational signatures may identify patients with breast cancer most likely to benefit from platinum-based chemotherapy
December 18, 2017: American Association for Cancer Research – “The presence in advanced breast cancer of mutational signatures characteristic of homologous recombination deficiency (HRD) was associated with improved clinical outcomes to treatment with platinum-based chemotherapy, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research.” Read more.
Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study
December 18, 2017: The Lancet – This study “aimed to estimate how vaccination against HPV, changes to the screening test, and falling screening coverage will affect cervical cancer incidence in England up to 2040.” Read the study.
Radiation dermatitis: recognition, prevention, and management
December 15, 2017: Cancer Network: “This article summarizes the current knowledge of the etiology, manifestations, and interventions available for prevention and management of radiation dermatitis.” Read more.
Ovarian cancer stem cells: unraveling a germline connection
December 14, 2017: Genetic Engineering & Biotechnology News – “Ovarian stem cells” expressing germline pluripotent markers serve as novel paradigm with potential to address infertility, menopause, and probably influence tumor initiation. Read more.
Cancer breakthrough: nanoparticle used to detect microtumors
December 13, 2017: Medical News Today: “New research conducted by Rutgers University has successfully used cutting-edge technology to spot minuscule, hard-to-detect cancerous tumors. The scientists hope that they will be able to successfully use this technique in humans in the near future.” Read more.
BELLE-3 Trial: Combination Therapy in Resistant Advanced Breast Cancer
December 13, 2017: ASCO Post – “The phase III BELLE-3 trial has shown prolonged progression-free survival but a worse safety profile with the addition of the pan-phosphoinositide 3-kinase inhibitor buparlisib to fulvestrant (Faslodex) in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer progressing on or after mTOR inhibition.” Read more.
NCI Center for Global Health’s Scientific Alliance with Kazakhstan on Women’s Cancer Research
December 13, 2017: The NCI provides an overview of activities and discussions held at the International Congress “Progress and Controversies in Gynecological Oncology and Breast Cancer” October 4-6, 2017 in Almaty, Kazakhstan. The goal of this conference was to improve the region’s access to quality oncology services through both international collaboration and the creation of a research platform in women’s cancer care. Read more.
Caring for the frail, older patient with cancer: four practical approaches
December 10, 2017: ASCO Post – “At the 2017 Palliative and Supportive Care in Oncology Symposium, Dr. Jatoi presented four practical approaches that may make therapeutic decisions easier for older cancer patients: consider clinical trial enrollment, use prognostic tools, employ geriatric assessment, and consider initial chemotherapy dose reductions.” Read more.
SABCS 2017: Temporary ovarian suppression with hormone analog may preserve fertility during breast cancer chemotherapy
December 7, 2017: ASCO Post – “Meta-analysis of individual patient data from five randomized clinical trials provided a high level of evidence that treatment with a gonadotropin-releasing hormone analog (GnRHa) could safely and effectively protect ovarian function and potentially preserve fertility in premenopausal women receiving chemotherapy for early-stage breast cancer, according to a study presented by Lambertini et al at the 2017 San Antonio Breast Cancer Symposium.” Read more.
Present and future cancer staging with the eighth edition of the AJCC Cancer Staging Manual
December 6, 2017: ACS Bulletin – “It has been more than one year since the American Joint Committee on Cancer (AJCC) published the eighth edition of the AJCC Cancer Staging Manual. The final pieces are in place for implementation of this edition on January 1, 2018.” Read more.
European Commission approves Tesaro’s Zejula as maintenance therapy for ovarian cancer
December 1, 2017: Ovarian Cancer News Today – “The European Commission has approved Tesaro‘s Zejula (niraparib) as a maintenance treatment for ovarian cancer, with or without BCRA mutations, in women who have shown a complete or partial response to platinum-based chemotherapy.” Read more.
Immune response predicts longer OS for ovarian cancer
November 30, 2017: Healio – “Women with high-grade serous ovarian cancer and high levels of cytotoxic CD8 appeared to have longer OS than those with low or no CD8, suggesting the presence of the cells may be a prognostic factor for patients, according to study results.” Read more.
PARP inhibitors continue to show promise in ovarian cancer
November 29, 2017: Cure Today – “It’s important that we start to use these drugs more and more and bring them sooner into the management of the individual,” said Campos, who reviewed trial data and approvals for several PARP inhibitors and looked at the potential for advancing the use of these agents.” Read Dr. Susana M Campo’s comments on several trials including NOVA, SOLO-2, STUDY 19 and ARIEL-3.
Platinum-free interval linked with survival in recurrent ovarian cancer
November 28, 2017: Journal of Clinical Pathways -“The length of time between the end of adjuvant platinum-based therapy and the recurrence of cancer is a strong predictor of survival in older women with recurrent ovarian cancer, according to a study published online in Gynecologic Oncology (online November 15, 2017; doi: 10.1016/j.ygyno.2017.11.008).” Read more.
SOTIO broadens its phase II clinical trial program in ovarian cancer
November 28, 2017: Pipeline Review.com – “SOTIO, a biotechnology company owned by the PPF Group, today announced the enrollment of the first patient to a Phase II study testing DCVAC/OvCa in combination with standard of care chemotherapy for patients with ovarian cancer after first relapse. Based on positive signals from ongoing trials, SOTIO is also expanding its ongoing study testing DCVAC/OvCa as a maintenance therapy in first line treatment of patients with ovarian cancer.” Read more.
Early referral, education keys to helping patients manage lymphedema
November, 25, 2017: Oncology Times – “Lymphedema can be a major and long-term concern for many cancer patients, but good communication and collaboration among the patient, the treating oncologist, and supportive-care professionals can lessen these impacts and help patients move forward with good quality of life.” Read more.
Prevalence of secondary cancers underscores need for trial inclusion
November 22, 2017: Healio – “A quarter of older adults newly diagnosed with cancer from 2009 to 2013 had a prior cancer history, according to an observational study published in JAMA Oncology. Additionally, 11% of patients aged younger than 65 years diagnosed during that period also had a prior cancer history, researchers reported.” Read more.
Nearly half of cancer cases are within your control, researchers say
November 21, 2017: Time – “Diseases as complicated as cancer are often caused by genetic factors that are out of your control and risk factors that you can change. Now, researchers have calculated just how much of that risk is within a person’s control.” Read more.
Causes of immunotherapy-related side effects in cancer require more research
November 21, 2017: Healio – “Oncologists and researchers should be more concerned with the lack of available data on the mechanisms of action behind significant immunotherapy-related adverse events in patients with cancer, according to a speaker at Chemotherapy Foundation Symposium.” Read more.
Endometrial cancer incidence rising in the US and worldwide
November 20, 2017: Diagnoses of endometrial cancer have increased worldwide in recent years, with rates rising in more than half of 43 countries studied during the decade that ended around 2010, a team of international researchers has shown. The study, published October 16 in the Journal of the National Cancer Institute, also showed that rates of the disease vary widely among countries. Rates are highest in North America and Europe and lowest in middle-income countries, such as India and South Africa. Read more.
Experimental ovarian cancer vaccine shows promise in mice
November 17, 2017: NIH – “The vaccine targets a protein that is present at elevated levels in approximately 90% of human ovarian epithelial cancers, the most common type of ovarian cancer. Study investigators showed that the vaccine inhibited the growth of ovarian cancers in mouse models of the disease.” Read more.
African American women face a more aggressive type of endometrial cancer: researchers can’t explain why
November 17, 2017: PBS – “It’s a puzzle with answers that have long eluded researchers: African American women are more likely to have a more aggressive form of endometrial cancer and more than twice as likely to die from it than white women, according to the American Cancer Society.” Read more.
Frequent bleeding outside of menstrual cycle may be sign of cancer
November 15, 2017: Dr. Toto Imam SpOG (K), gynecology and oncology expert at the Gatot Soebroto Military Hospital, said frequent bleeding outside of menstrual cycle may be a sign of cancer. The statement was delivered in the Seminar on Early Detection and Prevention of Reproductive Organs of Women in the Multifunction Room of Hermina Hospital in Bekasi, in cooperation with Cancer Information and Support Center (CISC), Wednesday (15/11/2017). Read more.
IUDs may have the power to fight cervical cancer, new study suggests
November 10, 2017: Observer – “In addition to being considered the most foolproof contraception method out there, a new study published in Obstetrics & Gynecology suggests intrauterine devices, or IUDs, may protect against cervical cancer.” Read more.
Endometrial cancer enters immunotherapy age
November 9, 2017: Onc Live – “The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors has helped propel endometrial cancer into the immunotherapy age, according to Martee L. Hensley, MD.” Read more.
Survey asks why some ovarian cancer patients choose maintenance therapy
November 10, 2017: Cure Today – “What do people who have primary and recurrent ovarian cancer expect from maintenance therapy? A survey of about 1,950 people who chose to move forward with maintenance therapy revealed that most of them were expecting to buy time — at least 6 months’ delay in disease progression.” Read more.
3D cultured spheroids could drive precision treatment for ovarian cancer
November 10, 2017: News Medical – “Honeycomb-like arrays of tiny, lab-grown cancers could one day help doctors zero in on individualized treatments for ovarian cancer, an unpredictable disease that kills more than 14,000 women each year in the United States alone. A team of researchers has devised a process that can grow hundreds of cultured cell masses, called spheroids, from just a few tumor cells derived from a patient.” Read more.
Experts concerned about cervical cancer in Africa
November 9, 2017: Xinhuanet – “Health experts expressed concern about the rate which women in Africa silently losing their lives to cervical cancer which is potentially preventable with vaccines and early diagnosis. They made the remarks while speaking at a panel session dubbed “cervix and gynecological cancers” at the sidelines of the 11th International Conference on Cancer in Africa (AORTIC 2017) that opened in the Rwandan capital Kigali.” Read more
PARPS bring excitement to ovarian cancer treatment
November 9, 2017: Onc Live – “PARP inhibitors offer exciting opportunities to improve outcomes for patients with ovarian cancer and hopefully will be moved to the front-line setting if the evidence warrants it, said Susana M. Campos, MD” Read more.
Survival predictors in ovarian cancer and current immunotherapeutic strategies
November 9, 2017: Cancer therapy advisor – “Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.” Read more.
Survey shows patients consider several factors of maintenance therapy for ovarian cancer treatment
November 8, 2017: Onc Live – “Patients with ovarian cancer (OC) were unified in their responses regardless of age, disease stage, or whether they had primary or recurrent disease, and were more likely to opt to receive maintenance therapy if it could offer delay of disease progression and allow patients to maintain or improve their quality of life (QoL), according to findings from a survey reported at the European Society of Gynaecological Oncology (ESGO) 2017 Congress.” Read more.
Pembrolizumab shows activity in advanced cervical cancer
November 8, 2017: Cancer Network – “The immune checkpoint inhibitor pembrolizumab demonstrated antitumor activity in a small trial of patients with advanced cervical cancer. The agent had a similar toxicity profile to that seen in other malignancies.” Read more.
Age, race linked to survival disparities for HPV-associated cancers
November 7, 2017: Healio – “The relative survival rate for an individual with HPV-associated cancer appeared largely dependent on demographic characteristics such as sex, race and age, according to a population-based study. White patients demonstrated higher 5-year survival than black patients for all HPV-related cancers and all age groups, suggesting large disparities exist, the research showed.” Read more.
Levels of immune cells within ovarian tumors linked to survival for some patients
November 6, 2017: NCI Cancer Currents Blog – “A large international study suggests that the presence of certain immune cells in the tumors of some patients with ovarian cancer are associated with improved survival.” Read more.
Robotic laparoscopy improves outcomes for patients with ovarian cancer, reaffirms role of surgery
November 6, 2017: Onc Live – “In a retrospective single-center study, investigators reviewed experience with robotic interval cytoreduction (IRC) following neoadjuvant chemotherapy for patients with advanced ovarian cancer who were treated between 2011 and 2016 at the University of Rochester Medical Center. After a mean of 3.9 cycles of neoadjuvant chemotherapy, 29 patients underwent IRC. One case (3.3%) was converted to an open versus robotic procedure because of extensive tumor not amenable to robotic cytoreduction.” Read more.
Mixed findings show dose-dense therapy noninferior to IP treatment in ovarian cancer
November 6, 2017: Onc Live – “Phase III findings of the ICON8 trial demonstrated that patients with ovarian cancer can safely undergo a 3-week dosing schedule of chemotherapy with paclitaxel versus a weekly dose-dense regimen, as neither approach was found to have a benefit in progression-free survival (PFS).” Read more.
For the first time, researchers control cells’ chromatin to prevent cancer from adapting to treatment
November 6, 2017: Medical Xpress – “Northwestern Engineering’s Vadim Backman has developed an effective new strategy for treating cancer, which has wiped out the disease to near completion in cellular cultures in the laboratory. The treatment works by controlling chromatin, a group of macromolecules—including DNA, RNA, and proteins—that houses genetic information within cellsand determines which genes get suppressed or expressed.” Read more.
New medications for the treatment of ovarian cancer
November 5, 2017: “In an article recently published in Gynecologic Oncology Research and Practice Herzog and Monk reviewed the currently available medications in the management of epithelial ovarian cancer. Platinum-containing induction chemotherapy has been the first-line treatment for women with advanced ovarian cancers. However, there have been conflicting studies on the role of maintenance chemotherapy after achieving an objective response during induction. Some studies show that maintenance chemotherapy is beneficial for patients with ovarian cancers while others say otherwise.” Read more.
PARP inhibitor may be effective against some triple-negative breast cancers lacking BRCA mutations
November 11, 2017: Amercan Association for Cancer Research – “The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that did not have BRCA mutations but had other alterations in DNA damage-repair pathways, according to results of a study published in Clinical Cancer Research” Read more.
Africa: First Lady – Africa needs to do more in the fight against cancer
November 8, 2017: All Africa – “Addressing the (AORTIC) participants, the First Lady highlighted the threat that cancer poses depicted by the 2015 World Health Organisation (WHO) report which stated that cancer accounted for 8.8 million deaths globally, 70 percent of which occurring in low and middle income countries, many of which are in Africa.” Read more.
Secondary cytoreductive surgery shows promise in ovarian cancer
November 7, 2017: Onc Live – In a phase III study of patients with platinum-sensitive recurrent ovarian cancer, the impact of secondary cytoreductive surgery was evaluated. The AGO DESKTOP III/ENGOT ov20 trial randomized patients to second-line chemotherapy alone versus cytoreductive surgery followed by chemotherapy. Read more.
No overall survival advantage in frontline Nintedanib with chemotherapy in advanced ovarian cancer
November 7, 2017: Onc Live – “The final analysis of overall survival (OS) data from the phase III AGO-OVAR 12 trial of nintedanib (Ofev) plus carboplatin/paclitaxel versus carboplatin/paclitaxel alone in women with chemotherapy-naïve advanced ovarian cancer did not demonstrate a survival advantage with the addition of nintedanib, according to the findings presented at the European Society of Gynaecological Oncology (ESGO) 2017 Congress.” Read more.
Dr. Sehouli Discusses Trial of Secondary Cytoreductive Surgery in Ovarian Cancer
November 7, 2017: Onc Live – “Sehouli says that surgery is the cornerstone of primary treatment for ovarian cancer, followed by subsequent chemotherapy with platinum combinations. The role of surgery in the relapsed setting is not as defined though.” See the interview.
Study reveals large disparities in survival for patients with HPV-associated cancers
November 6, 2017: Medical Xpress – “A new study found large disparities by sex, race, and age in survival for patients diagnosed with different cancers caused by the human papillomavirus (HPV). Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings suggest that improvements in HPV vaccination and access to cancer screening and treatment are needed.” Read more.
AKT1 E17K mutation targetable in various tumors through AKT inhibition
November 3, 2017: Onc Live – A multihistology basket study proved the targetability of the AKT1 E17Kmutation in human cancers by treating patients with various types of cancer harboring an AKT1 E17K mutation with AZD5363, an oral pan-AKT inhibitor, according to findings published in the Journal of Clinical Oncology. 1 The PI3K/AKT pathway is one of the most frequently activated pathways across cancers and can be triggered by one of several mutations.” Read more.
‘Super T cells’ engineered for optimal performance drive new gene-therapy approach
November 3, 2017: Medical Xpress – “What we see over and over in trying to treat some of the most aggressive and intractable cancers, including many lung, brain, ovarian, breast, melanoma and sarcoma tumors, is that the tumor fights back. The area around the tumor is a hostile environment that disarms immune cells and deprives them of the ability to kill tumor cells. We have identified a major pathway by which these kinds of cells try to disable immune cells, and formulated a strategy for exploiting that weakness,” says the study’s principal investigator, Kunle Odunsi.” Read more.
Precision radiooncology enables women to maintain an active sex life after gynaecological radiotherapy
November 2, 2017: Medical Xpress – “This is due to the combination of three mainstays of precision medicine in radiooncology: optimum prevention, precise irradiation of the tumour and subsequent sexual counselling. Preventive measures include even more careful planning of radiotherapy to direct a high dose of radiation at the tumour while sparing healthy tissue and surrounding organs, including part of the vagina, as far as possible.” Read more.
Alcohol and Breast Cancer Infographic
November 2, 2017: Cassiobury Court shares an infographic summarizes recent studies that say drinking moderate amounts of alcohol could increase the risk of getting breast cancer. See more.
HPV status linked to overall and disease-free survival in vulvar cancer
November 1, 2017: Cancer Therapy Advisor – “Women with vulvar cancers who test positive for human papillomavirus (HPV) may have improved survival compared with HPV-negative patients, according to a study published in the International Journal of Cancer. Although women with HPV are at an increased risk of developing malignancies such as oropharyngeal, cervical, vulvar, and vaginal cancers, previous studies have shown that the HPV status of a patient may predict survival.” Read more.
Maintenance Poly (ADP-ribose) Polymerase inhibitor therapy for ovarian cancer: precision oncology or one size fits all?
November 1, 2017: Journal of Clinical Oncology – “Platinum/taxane combinations are the most effective regimens for treatment of epithelial ovarian cancer. Response varies between patients, but because the molecular basis for resistance is not defined, patients receive so-called one size fits all therapy.” Read the full article.
New blood test developed to diagnose ovarian cancer
October 31, 2017: EurekAlert! – “Investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute are leveraging the power of artificial intelligence to develop a new technique to detect ovarian cancer early and accurately. The team has identified a network of circulating microRNAs – small, non-coding pieces of genetic material – that are associated with risk of ovarian cancer and can be detected from a blood sample.” Read more.
Robot-assisted surgery costs more but may not be better
October 30, 2017: The Wall Street Journal (subscription required)- “Robot-assisted surgeries—a technology oft-touted by hospitals—are longer and more expensive than other types of minimally invasive surgeries, according to a growing body of studies. And in some types of surgery, they have a lower success rate.” WSJ discusses two studies in JAMA comparing robotic-assisted surgeries to laparoscopic.
Must-read advice from black doctors on preventing and battling cancer
October 26, 2017: Essence – “African-Americans have the highest death rate and shortest survival of any racial group in the United States for most cancers. “I tell women that if cancer is more aggressive in Black women, then you have to be more aggressive in taking care of yourself,” says B. Lee Green, Jr., Ph.D.” Read more.
Genomic profiling identifies patients most likely to respond to immunotherapy
October 25, 2017: Oncology Times – “This is the first time the FDA has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. With this approval, pembrolizumab is now indicated for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have microsatellite instability-high (MSI-High) or mismatch repair (MMR) deficiency.” Read more.
Frequent need to urinate could be a sign on ovarian cancer
October 25, 2017: Techtimes – “Needing to use the toilet more often than usual is a symptom of ovarian cancer. Findings of a new survey, however, have revealed that only 1 percent of women are aware of this warning sign.” Read more.
Expert discusses immunotherapy across gynecologic malignancies
October 23, 2017: Onc Live – “Immunotherapy is slowly evolving in the gynecologic malignancies landscape and has moved beyond only having a role in ovarian cancer, according to Dmitriy Zamarin, MD, PhD.” Read more of this interview.
New treatment options offer hope for Saudi ovarian cancer patients
October 23, 2017: Arab News – “Dr. Faisal Al-Safi, section head and consultant in gynecologic oncology, department of oncology at the King Abdul Aziz Medical City/National Guard Health Affairs, said that ovarian cancer therapy has been improving due to the development of scientific research particularly during the last five years, which led to important strides offering more promising solutions for the disease, which causes an annual mortality of around 150,000 women globally.” Read more.
Extensive lymph node removal doesn’t improve survival in some women with early-stage breast cancer
October 10, 2017: Cancer.gov – “Long-term results from a large clinical trial confirm that, for some women with early-stage breast cancer who have lumpectomy as their surgical treatment, a less extensive lymph node biopsy approach is sufficient.” Read more.
As cancer tears through Africa, drug makers draw up battle plan
October 7, 2017: New York Times – “Under the new agreement, the companies — Pfizer, based in New York, and Cipla, based in Mumbai — have promised to charge rock-bottom prices for 16 common chemotherapy drugs. The deal, initially offered to a half-dozen countries, is expected to bring lifesaving treatment to tens of thousands who would otherwise die.” Read the NY Times article.
Death rates dropping, but racial disparities remain in breast cancer
October 3, 2017: Oncology Nursing News – According to a recent study released by the American Cancer Society, “From 2006 to 2015, there was a decrease in deaths in all groups. But, the death rate among non-Hispanic Black women continued to be higher than non-Hispanic white women.” Read more.
Dr. Ginsburg on genetic testing guidelines for gynecologic malignancies
October 3, 2017: Onc Live – Dr. Ophira Ginsburg in a video interview regarding NCCN guidelines for genetic testing. See the interview.
Celsion announces final clinical and traslational research data from its OVATION study at the AACR special conference on ovarian cancer
October 3, 2017: Global Newswire – “Final clinical and translational research data from its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company’s DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced Stage III/IV ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.” Read the press release.
ASTRO 2017: GOG-249 confirms adjuvant pelvic radiation as standard of care for high-risk, early stage endometrial cancer
September 29, 2017: ASCO Post – “In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I–II high-risk endometrial cancer were not superior following adjuvant vaginal cuff brachytherapy plus chemotherapy when compared with adjuvant pelvic radiation therapy.” Read more.
Acelarin-Paraplatin combo shows high disease control rates in phase 1b trial for ovarian cancer
September 29, 2017: Ovarian Cancer News Today – “Nearly all ovarian cancer patients enrolled in NuCana‘s Phase 1b trial benefited from the combination of Acelarin (NUC-1031) plus Paraplatin (carboplatin), according to data presented at the recent European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.” Read the article.
Third CDK blocker approved for breast cancer
September 28, 2017: MedPage Today – “The FDA approved abemaciclib (Verzenio) for treatment of hormone receptor-positive, HER2-negative breast cancers that have progressed while patients were on endocrine therapy.” Read more.
More expansive genetic testing needed in ovarian cancer
September 28, 2017: Cure Today – “More research is needed on the other genetic mutations, besides BRCA, that patients with ovarian cancer harbor so that they can be used to help plan treatments.” Read more.
Ovarian cancer care: What PCPs need to know
September 27, 2017: Healio interviews Dr. Stephanie Blank regarding primary care physicians and their role in prevention, screening of ovarian cancer and more. Read the interview.
Genelux initiates phase 2 clinical trial of GL-ONC1 in recurrent ovarian cancer
September 27, 2017: “Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, today announced that it has treated the first patient in a Phase 2 clinical trial in recurrent ovarian cancer, with its lead clinical-stage candidate, GL-ONC1.” Read the press release.
Pelvic radiation remains standard treatment for early-stage endometrial cancer
September 26, 2017: Healio – “Vaginal cuff brachytherapy with chemotherapy did not extend RFS or OS compared with pelvic radiation therapy for women with stage I or stage II high-risk endometrial cancer, according to phase 3 results of the Gynecology Oncology Group-249 trial presented at the American Society for Radiation Oncology Annual Meeting.” Read the article.
Marcus E. Randall, MD, on endometrial cancer: results from a gynecology oncology group study
September 2017: ASCO Post – “A video interview with Dr. Randall on the phase II study findings on pelvic radiation therapy vs vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early stage endometrial cancer.” Watch the video.
Solange Peters, MD, PhD and Mary Gospodarowicz, MD, on mentoring women in oncology: an international perspective
September 2017: ASCO Post – A video interview with Dr. Mary Gospodarowicz, a recipient of the 2017 Women who Conquer Cancer Mentorship Award. See the interview.
New hope for ovarian cancer
September 25, 2017: Mayo Clinic – interview with an ovarian cancer survivor discussing the new treatments available and the hope they bring. Read the piece.
The high cost of new cancer therapies – a challenge of inequality for all countries
September 2017: JAMA Network – Viewpoint article on the high cost of cancer drugs and the need to take action. Login required to Read the full article.
The HPV vaccine gains ground amoung US teenagers
September 22, 2017: New York Times – “More than half of all American teenagers are getting vaccinated against human papillomavirus, and the rate is rising over time, according to a new report from the Centers for Disease Control and Prevention.” Read more.
Bevacizumab extends survival in advanced cervical cancer
September 22, 2017: Healio – “The addition of bevacizumab to chemotherapy continued to show significant survival benefits in women with advanced cervical cancer, according to final analysis of a randomized, open-label, phase 3 trial published in The Lancet.” Read more.
New genetic test for predicting cancer recurrence
September 21, 2017: Medical Xpress – “Researchers have discovered a new genetic test which could help predict cancer recurrence – paving the way for more precise, personalised treatments.” Read more.
HPV self-sampling could boost cervical cancer screening rates in transgender men
September 20, 2017: Healio – “Transgender men are less likely to be screened for cervical cancer than cisgender women. About half of the transgender men surveyed reported they had not received a Pap smear within the past 3 years.” Read more.
Gardasil 9 vaccine seen as effective cervical cancer combatant, study finds
September 15, 2017: Life Science Daily – “Results determined Gardasil 9 showed 97.4 percent efficacy to prevent infections and disease caused by the five additional HPV genotypes not included in the four-valent Gardasil vaccine.” Read more.
ESMO 2017: Study confirms chemoradiation is best treatment for locally advanced cervical cancer
September 14, 2017: ASCO Post – A 14-year randomized trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings were reported at the European Society for Medical Oncology (ESMO) 2017Congress in Madrid (Abstract 928O_PR). Read more.
Avastin Clone OK’d – Biosimilar for bevacizumab approved for various cancers
September 14, 2017: MedPage Today – “Amgen’s biosimilar for the angiogenesis-inhibiting biologic drug bevacizumab, to be sold as Mvasi, was approved…by the FDA.” Read more.
The crisis in gynecologic cancer research
September 14, 2017: This New York Times editorial discusses the drop in the number of gynecologic cancer clinical trials by 90 percent from 2011 to 2016 in the United States. Read the story from the NYT.
Editorial Article: Epigenetic biomarkers in gynecological cancers explored
September 14, 2017: Dr. Lewis Francis, of Swansea University, discusses ChIP methods used in his research on the role of epigenetics in ovarian and endometrial cancers. Read the interview.
Multivitamins tied to reduced risk of chemo-induced neuropathy
September 13, 2017: HealthDay News — “Multivitamin use before diagnosis of breast cancer is associated with reduced risk of symptoms of chemotherapy-induced peripheral neuropathy (CIPN), according to a study published online September 1 in the Journal of the National Cancer Institute.” Read more.
Is genetic testing for cancer survivors underutilized?
September 13, 2017: “More than 80% of women with a history of either breast or ovarian cancer may not be receiving necessary genetic testing, according to a new study in the Journal of Clinical Oncology.” Read more.
Preventing cancer and other diseases caused by Human Papillomavirus infection: 2017 Lasker-DeBakey Clinical Research Award
September 12, 2017: JAMA Network – “The 2017 Lasker-DeBakey Clinical Medical Research Award has been presented to Douglas Lowy and John Schiller for development of the virus-like particle technology that was used to create the human papillomavirus vaccine to prevent cervical cancer and other diseases.” Read the article.
For many women, cervical cancer screening may get a lot simpler
September 12, 2017: NPR discusses the impact of the new draft recommendations from the US Preventative Services Task Force. Read the article.
Who is the current Minister of Health in Nigeria 2017?
September 12, 2017: Professor Isaac Adewole has recently taken over the position of minister of health in Nigeria. Before he was appointed to become the minister he was a Professor of Obstetrics and Gynaecology at the College of Medicine, University of Ibadan. Read more.
No PFS gain with dose-dense weekly chemotherapy in epithelial ovarian cancer
September 11, 2017: medwireNews: “The 3-weekly regimen of carboplatin and paclitaxel should remain the first-line standard of care for women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, say the ICON8 researchers who did not find a progression-free survival (PFS) benefit with dose-dense weekly chemotherapy.” Read more.
Understanding racial disparities in endometrial cancer
September 10, 2017: Oncology Times – Dr. Kemi Doll “is ambitiously engaged in a multi-pronged, ‘360-degree’ research project to detect endometrial cancer diagnosis and treatment pathways, as well as the delay of the same, particularly for black women.” Read more.
A look at glucose metabolism in ovarian cancer
September 10, 2017: “A new study of non-diabetic women with ovarian cancer reveals a potential correlation and area for further study regarding the expression of the GLUT1 glucose transporter receptor at the cancer tissue level.” Read more about the study in Oncology Times.
Precision Medicine: A new era for ovarian cancer
September 10, 2017: Oncology Times published a study on genomics, clinical trial enrollment and research directions. Read the article.
Concomitant chemoradiation should be standard for locally advanced cervical cancer
September 10, 2017: Healio.com reports: “Neoadjuvant chemotherapy followed by radical surgery did not improve outcomes compared with cisplatin-based concurrent chemoradiation for women with locally advanced squamous carcinoma of the cervix, according to results of a randomized controlled trial presented at the European Society for Medical Oncology Congress.” Read more.
Reproductive potential can be maintained after ovarian tissue transplant
September 10, 2017: Healio.com reports: “Ovarian tissue preservation, subsequent transplantation and maintenance of reproductive potential may be feasible for women with breast cancer who have BRCA mutations, according to a retrospective analysis presented at the European Society for Medical Oncology Congress.” Read more.
Dr. Mirza on niraparib plus bevacizumab combo in ovarian cancer
September 10, 2017: Onc Live.com: “Mansoor Raza Mirza, MD discusses phase I results of a trial exploring the combination of niraparib (Zejula) and bevacizumab (Avastin) in patients with platinum-sensitive epithelial ovarian cancer.” See the video.
Nirapatib maintains quality of life in recurrent ovarian cancer
September 8, 2017: Oncology Nurse Advisor reports: “Administering niraparib to patients with recurrent ovarian cancer after a complete response (CR) or partial response (PR) to platinum-based chemotherapy may allow patients to continuously maintain their quality of life (QOL) during treatment, according to a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress.” Read more.
New data confirms standard dosing of chemotherapy in ovarian cancer treatment
September 6, 2017: Women with ovarian cancer can safely stick to the standard 3-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid. Read more.
Five important updates in gynecologic cancer
September 1, 2017: Healio.com sums up five updates about screening and treatment of gyn cancers.
Cancer patients still facing lack of information about
August, 31, 2017: Patients undergoing cancer treatment are still not getting enough support when it comes to the impact that the disease and its treatment has on their fertility, a new study has discovered. Read more from FIGO news.
Does baby powder cause cancer? A jury says yes. Scientists aren’t so sure.
August 22, 2017: Read the story from NPR.
Palliative care reduces aggressive treatment of advanced cancer
August 22, 2017: Exposure to palliative care considerably reduced health care utilization among Medicare beneficiaries with advanced cancer, according to observational study results published in Journal of Oncology Practice. Read more from Healio.com.
Platinum therapy should not be delayed in ovarian cancer relapse
August 22, 2017: Platinum-based chemotherapy (PBC) should not be delayed in favor of non-platinum-based therapy (NPBC) in patients with partially platinum-sensitive ovarian cancer (OC), according to a study published in the Journal of Clinical Oncology. Read more from Cancer Therapy Advisor.
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
August 22, 2017: Nature Communications published a study online reporting analyses of 160 BRCA1 and BRCA2 germline mutation-associated breast and ovarian tumors. Read the study.
Lynparza receives additional FDA approval for ovarian cancer
August 21, 2017: From Managed Care: “The PARP inhibitor olaparib (Lynparza, AstraZeneca/Merck) has received FDA approval for a broader indication in ovarian cancer cases, including a new tablet formulation that will ease women’s pill burden.” Learn more about the specific approvals.
Addition of CA4P to bevacizumab confers modest PFS benefit in platinum-resistant ovarian cancer
August 17, 2017: Healio reports: “A second interim analysis of a trial designed to evaluate the addition of CA4P to standard therapy for patients with platinum-resistant ovarian cancer showed a small PFS benefit for the combination. However, the difference did not reach statistical significance.” Read more.
Clinical trial stirs controversy over power morcellator bags
August 16, 2017: “A clinical trial scheduled to evaluate the safety and efficacy of a bag designed to catch cancerous tissue from power morcellation in women undergoing laparoscopic hysterectomies has rekindled debate in the gynecologic community over the controversial procedure.” Read about the study on Healio.com.
Sexual dysfunction in women with cancer: a review of available interventions
August 15, 2017: Oncology Nurse Advisor reports: “According to a study published in the European Journal of Cancer Care, cancer diagnosis and treatment have varied social, psychological, and physical impact on sexual health and may decrease quality of life for women.” Read more.
Expert discusses promise of Mirvetuximab Soravtansine in ovarian cancer
August 14, 2017: Onc Live reports: “Mirvetuximab soravtansine (IMGN853) demonstrated a favorable toxicity profile and encouraging clinical activity in patients with epithelial ovarian cancer, according to a pooled analysis of phase I expansion cohorts that was presented at the 2017 ASCO Annual Meeting.” Read more.
Dr. Chase on future treatment landscape of gynecologic malignancies
August 10, 2017: Onc Live posted a video interview with Dana M. Chase on the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer. Watch the video.
Identifying essential genes for cancer immunotherapy
August 9, 2017: ASCO Post – “A new study published by Patel et al in Nature identifies genes that are necessary in cancer cells for immunotherapy to work—addressing the problem of why some tumors don’t respond to immunotherapy, or respond initially but then stop as tumor cells develop resistance to immunotherapy.” Read the discussion.
Dr. Arend discusses MSI testing in gynecologic malignancies
August 9, 2017: Onc Live posts a video interview with Dr. Rebecca Arend, MD regarding microsatellite instability (MSI) testing in patients with gynecologic malignancies. See the video.
Bevacizumab OS benefit confirmed in cervical cancer
August 8, 2017: Onc Live reports: “Adding bevacizumab (Avastin) to chemotherapy improved overall survival (OS) for women with cervical cancer, according to final results from the phase III GOG 240 trial published online in The Lancet.” Read more.
NCI study identifies essential genes for cancer immunotherapy
August 7, 2017: NIH – “A new study identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why some tumors don’t respond to immunotherapy or respond initially but then stop as tumor cells develop resistance to immunotherapy.” Read more.
Opioid use common among cancer survivors
August 7, 2017: Healio reports: “Cancer survivors, even those 10 years or longer past diagnosis, had 1.22-times higher prescription opioid use than matched individuals without a history of cancer, according to results of a population-based study.” Read the Healio article. Read the original study.
New data address critical surgical questions in ovarian cancer
August 4, 2017: Dr. Maurie Markman discusses two abstracts presented at the 2017 ASCO meeting: LION Study (Lymphadenectomy in Ovarian Neoplasms) and Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer. Watch the video or read the transcript.
Surgeons and the opioid epidemic: Treatment and education strategies for the practicing surgeon
August 2, 2017: The American College of Surgeons released a bulletin to address issues surgeons are facing regarding opioids. The bulletin includes Implicit bias and the perception of pain, opioid treatment of chronic pain, opioid management training and a general approach to improved treatment of surgical pain. Read the bulletin.
Celsion announces latest translational data from the OVATION Study in newly diagnosed advanced ovarian cancer patients
August 2, 2017: Nasdaq reports: “findings from the translational research data from its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer who will undergo neoadjuvant chemotherapy (NACT) followed by interval debulking surgery.” Read the press release.
Lower body lymphedema in patients with gynecologic cancer
August 2017: This International Journal of Cancer Research and Treatment review “focuses on secondary lymphedema due to gynecologic cancer treatment, analyzing its incidence in the different types of gynecologic cancer, diagnosis, risk factors, impact on QoL and treatment.” Read the study.
77-year-old cancer patient undergoes robotic surgery
July 31, 2017: The Times of India reports the benefits of robotic surgery and an instance in which it was used for an ovarian cancer patient. Read the article.
Bristol-Myers Squibb, Clovis Oncology to evaluate nivolumab-rucaparib combination
July 31, 2017: Healio reports: Bristol-Myers Squibb and Clovis Oncology entered a clinical collaboration to evaluate the combination of nivolumab and rucaparib for treatment of three tumor types. The collaboration will include two pivotal phase 3 trials and one phase 2 trial designed to assess the PD-1 checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb) in combination with the PARP inhibitor rucaparib. Read more.
Is it possible to get pregnant after endometrial cancer? An oncologist explains
July 30, 2017: Kelly Mullen McWilliams blogs about uterine cancer and pregnancy. Read the blog.
Molecular similarities discovered among endometrial cancers
July 28, 2017: Healio reports: “Clear cell endometrial cancer appeared to have molecular similarities with serous endometrial cancer and endometrioid endometrial cancer, according to a study published in Cancer.” Read the article.
Researchers to present clinical data supporting use of Xoft System for endometrial cancer treatment at American Association of Physicists in Medicine Annual Meeting & Exhibition
July 27, 2017: EconoTimes reports: “Researchers from Miguel Servet University Hospital in Zaragoza, Spain will present preliminary findings from their recent clinical experience treating 36 endometrial cancer patients with electronic brachytherapy using the Xoft System at the AAPM meeting. The dosimetric analysis showed that electronic brachytherapy with the Xoft System delivered a lower dose of radiation to surrounding healthy organs at risk in patients with endometrial cancer, such as the bladder and rectum, than would have been delivered by treatment with Ir-192 or Co-60 sources.” Read more.
Challenges in international comparison of health care systems
July 27, 2017: The JAMA Netowrk published a “viewpoint” article on the differences between health care systems across the globe and how they can be compared despite these differences. Read the article.
Complementary cancer therapies: fatigue and exercise
July 27, 2017: Cure Today published an opinion piece on the positive impact of exercise for cancer patients and survivors. Read the article.
Olaparib tablets prolong progression-free survival in ovarian cancer
July 26, 2017: Cancer Therapy Advisor reports: “Maintenance treatment with olaparib tablets may prolong progression-free survival (PFS) without negatively affecting quality of life among patients with relapsed ovarian cancer, according to a study published in The Lancet Oncology.” Read more
How PARP inhibitors might prove useful in more than just BRCA cancers
July 26, 2017: FierceBiotech reports: “Scientists led by the University of Pennsylvania believe Lynparza may be able to kill cancer cells that don’t have the mutations—provided it’s paired with a helper compound.” Read more.
Cancer patients in chemo ward may influence each other’s survival
July 25, 2017: Reuters Health reports: “Who a cancer patient spends time with in the chemotherapy ward may have a small but significant effect on their likelihood of surviving the disease, suggests a small study in the UK.” Read the article.
Doctors receiving training in cervical cancer surgery
July 24, 2017: The Himalayan Times report that “doctors of Bhaktapur Cancer Hospital and Nepal Cancer Relief Society have been undergoing surgical training in gynecologic oncology from Health Volunteers Overseas, USA.” Read more.
Breast cancer due to non-brca1 and non-BRCA2 mutations in Ashkenazi Jewish Women
July 20, 2017: JAMA Network posts an audio file of an interview with Mary-Claire King, author of Genetic Predisposition to Breast Cancer Due to Mutations other than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. Listen to the interview.
Nivolumab active in advanced gynecologic cancers
July 19, 2017: Onc Live reports: from ASCO 2017: “In phase I/II results from CheckMate-358, nivolumab (Opdivo) demonstrated clinical activity in women with recurrent/metastatic cervical cancer, and was active to a lesser extent in vaginal and vulvar cancers.” Read more.
Task force maintains recommendation against ovarian cancer screening
July 18, 2017: Drs. Maurie Markman and Richard Penson agree with the US Preventative Services Task Force advising “against screening for ovarian cancer in women who have no signs or symptoms, noting that screening does not decrease the number of deaths from ovarian cancer and may lead to women having unnecessary surgery.” Read more.
FDA ODAC recommends biosimilar bevacizumab and trastuzumab
July 18, 2017: The European Society for Medical Oncology reports the recent FDA recommendation regarding these two drugs. Read more.
Preventative mastectomies provide little survival benefit for ovarian cancer patients, study finds
July 17, 2017: Ovarian Cancer News Today reports: “Mastectomies and the removal of ovaries and fallopian tubes are considered preventive measures for women carrying BRCA genetic mutations linked to breast and ovarian cancer. But for women who have already had ovarian cancer, a risk-reducing mastectomy is not cost-effective and provides few survival benefits, according to researchers at Duke University Medical Center.” Read more.
Rethinking the ASCO Resource Stratified Cervical Cancer Screening Guidelines in the context of existing health infrastructure in basic settings
July 17, 2017: The Journal of Clinical Oncology publishes a response to the ASCO guideline challenging two of the recommendations the believe overlook opportunities to use existing health infrastructure in low- and middle-income countries. Read the correspondence.
With cancer screening, better safe than sorry?
July 17, 2017: The New York Times editorial discusses the risks and benefits of cancer screening as well as providing a list of US screening guidelines for different cancers. Read the article.
High-grade dysplasia increases long-term risk for HPV-related cancers
July 17, 2017: Healio.com reports: “Women maintained an increased risk for premalignancies and carcinomas of the anus, vulva, vagina and oropharynx 20 years after cervical intraepithelial neoplasia grade 3 diagnosis, according to results of a population-based study.” Read more.
Novel agent produces highest OS to date in PRmCC
July 14, 2017: Clinical Oncology reports: “Data from a multicenter trial of a novel targeted immunotherapy for the treatment of persistent/recurrent or metastatic cervical cancer (PRmCC) have yielded historic results: a 12-month overall survival (OS) of 38%, exceeding OS rates of more than 20 other clinical trials conducted in this area over nearly two decades.” Read more.
Cervical Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
July 13, 2017: Annals of Oncology publishes ESMO cervical cancer guidelines focusing on the management, follow-up, long term implications and survivorship as well as a new treatment algorithm. Read the guidelines.
Clinical trials are the way forward for ovarian cancer, but they need advocates at every level
July 9, 2017: Cure Today reports: “For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are available.” Read more.
The road ahead for ovarian cancer
July 8, 2017: Cure today reports: “Opening the 20th Annual Ovarian Cancer National Conference in Chicago, John Moroney, M.D., underscored the challenges that remain in the early detection and treatment of ovarian cancer, but also the tremendous hope that resides in robust clinical trial research.” Read the full article with more quotes from Dr. Moroney.
Incidence and prevalence of cancer in Colombia: the methodology used matters
July 6, 2017: Study published in ASCO’s Journal of Global Oncology compares real-world data from the health care system and estimates from cancer registries to determine a more precise estimation of patients with cancer in Colombia. Read the study.
Rates of pregnancy significantly lower in cancer survivors compared with general population
July 6, 2017: Oncology nurse advisor reports: A large scale population study revealed that girls and women aged 39 years and younger may be up to 38% less likely to achieve pregnancy after surviving cancer vs patients who have never had cancer. Read more.
Web-based symptom self-reporting improves survival
July 6, 2017: ClinicalOncology.com reports: “Having patients proactively report symptoms through a web-based tool improved survival in patients receiving routine outpatient chemotherapy, according to results from a Phase III trial. The approach increased median overall survival by five months compared with usual care.” Read more.
HPV triage after abnormal cervical cytology detects CIN earlier
July 5, 2017: Cancer Network reports “Women who undergo human papillomavirus (HPV) testing following a test showing abnormal cytology have earlier detection of high-grade cervical intraepithelial neoplasia (CIN), compared to those who do not undergo HPV testing, according to a new study. The higher rates of detection come at the expense of increased biopsy and electrosurgical excision rates.” Read more.
Angle’s ovarian cancer test could beat current standard
July 5, 2017: “UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer.” Read more.
PARP inhibitor shows promise in ovarian cancer
July 5, 2017: “Results of the ARIEL3 study of rucaparib (Rubraca) show promise for the drug’s potential in helping women with advanced ovarian cancer, according to Boulder, Colo.-based Clovis Oncology, a biopharmaceutical company that specializes in cancer treatments.” Read more.
Celsion announces completion of OVATION study and provides update on its immunotherapy trial in advanced stage III and IV ovarian cancer
July 5, 2017: GlobeNewswire reports “Celsion Corporation (NASDAQ:CLSN) today provided an update on its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with neoadjuvant chemotherapy for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer followed by interval debulking surgery.” Read the announcement.
FDA grants orphan drug designation to ALM201 for ovarian cancer
July 5, 2017: Healio.com announces: “ALM201 (Almac Discovery) is a therapeutic peptide developed to imitate properties of the FKBPL protein, a naturally secreted protein that has effects on multiple tumor biology processes, including cancer stem cells and angiogenesis.” Read the announcement.
The adoption of single-port laparoscopy for full staging of endometrial cancer: surgical and oncology outcomes and evaluation of the learning curve
June 26, 2017: The Journal of Minimally Invasive Gynecology published results of a retrospective study regarding the “safety, feasibility, learning curve, and surgical outcome for single-port laparoscopic full staging of endometrial cancer” finding that it is a safe and feasible technique. Read the abstract.
Controlling natural cell mechanism may open door to new cancer therapies
June 26, 2017: GEN news reports on a study published in Nature Communications that looks at controlling the natural physiological processes of cells, possibly halting the progress of disease. Read more.
A 2-minute test staves off cervical cancer
June 24, 2017: The Hindu.com reports on the work of the Kwiat Kobiecości (Flower of Womanhood) society, an organization providing information and resources to women in Poland. Read the article.
HPV screen detects more lesions but at cost of overtreatment
June 22, 2017: MedPage Today reports: “HPV tests resulted in faster and more complete diagnosis of precancerous lesions than Pap smears alone, but also led to more biopsies and surgical treatment of low-grade lesions, according to a new analysis of the New Mexico HPV Pap Registry published in JAMA Oncology.” Read more.
Combination demonstrates activity in endometrial cancer
June 21, 2017: Healio reports: “The combination of lenvatinib and pembrolizumab conferred benefit to previously treated patients with metastatic endometrial cancer, according to study results presented at the ASCO Annual Meeting.” Read more.
Risks of breast, ovarian and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
June 20, 2017: The JAMA Network published the results of a study to estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location. Read the study findings.
Tumor marker associated with poor ovarian cancer outcomes
June 19, 2017: Healio.com reports Women with advanced ovarian cancer who expressed the tumor antigen NY-ESO-1demonstrated shorter PFS and OS than those without the antigen, according to study results published in Gynecologic Oncology. Read more.
Clovis Oncology (CLVS) reports topline data on confirmatory phase 3 ARIEL3 trial of rucaparib; significantly improved progression-free survival in all ovarian cancer patient populations
June 19, 2017: “PFS was also improved in the rucaparib group compared with placebo by blinded independent central review (BICR), a key secondary endpoint.” Read more from the CLVS press release regarding study results.
POINT/COUNTERPOINT: Primary debulking surgery vs. neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer
June 15, 2017: Drs. Renee Cowan and Dennis Chi debate that cytoreductive surgery is the best way to affect survival outcomes while Drs. Anna Fagotti and Giovanni Scambia make the case that in a significant percentage of patients, neoadjuvant therapy yields equivalent survival, with better quality of life and lower costs. Read the point and counterpoint reported by cancernetwork.com.
The hunt continues for early ovarian cancer clues
June 14, 2017: The JAMA Network Medical News and Perspectives article details the challenges in prevention and screening for ovarian cancer. Read the article.
The paradoxical benefits of a web app for cancer patients
June 11, 2017: Forbes reports a new web-based tool currently in development with the goal to improve communication between patients and oncologists in which cancer patients can report symptoms weekly. Read more.
Better delivery method sought for high-dose chemo known to treat residual ovarian cancer
June 9, 2017: Ovarian Cancer News Today reports: “A recent study aimed to define the most effective chemotherapy dosage to successfully shrink tumors after surgery in women with residual ovarian cancer spread throughout the abdomen. It found that the effectiveness of chemotherapy strongly relies on the outcome of the initial surgery to remove as many tumors as possible.” Read more.
Liquid biopsies: too soon for cancer detection
June 8, 2017: Medscape reports: ” While the idea of using a drop of blood to detect an occult cancer is still elusive, use of so-called liquid biopsies for cancer screening is at least a little closer to reality with the development of a new high-intensity genomic sequencing approach outlined here at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting.” Read more (free login required).
‘Very high risk’ of blood clots in ovarian cancer patients who have chemo before surgery
June 8, 2017: “More than 25 percent of patients undergoing chemotherapy before and after surgery for ovarian cancer develop blood clots, according to a new retrospective cohort study from researchers at the University of Michigan Comprehensive Cancer Center.” Read more.
No survival benefit with node dissection in ovarian cancer
June 7, 2017: Presented at ASCO 2017: “Lymph node dissection had no impact on survival among women with completely resected ovarian cancer and clinically negative nodes, a large randomized trial showed.” Read more from MedPage Today.
High risk women with endometrial cancer often do not receive genetic counseling referral
June 5, 2017: According to a study presented by Dr. Stephanie Blank at ASCO 2017, “Genetic testing is likely underutilized for patients with endometrial cancer. By identifying mutations in women with endometrial cancer, we can heighten screening for other cancers and test family members.” Read more of this Healio article and interview with Dr. Blank.
HPV vaccine reduces high-risk infections, are people getting vaccinated?
June 4, 2017: Pharmacy Time reports: “The efficacy of the human papillomavirus (HPV) vaccine continues to be impressive, with newly reported findings showing that it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine; however, low vaccine uptake remains a concern.” Read more.
No QoL decrement with olaparib for recurrent ovarian cancer
June 4, 2017: Dr. Michael Friedlander reported at the 2017 ASCO meeting, “Treatment with olaparib led to a significant improvement in the primary endpoint of investigator-assessed progression-free survival versus placebo and in the secondary time-dependent efficacy endpoints of time to first subsequent therapy (TFST), second progression-free survival (PFS2), and time to second subsequent therapy (TSST).” Read more of his interview with Targeted Oncology.
Olaparib/cediranib combination leads to continued PFS improvement in ovarian cancer
June 4, 2017: Dr. Joyce Liu reported at the 2017 ASCO meeting, PFS continues to be superior with the combination of cediranib maleate and olaparib (Lynparza) compared with olaparib alone in patients with recurrent platinum-sensitive ovarian cancer.” Read more from Targeted Oncology.
ASCO 2017: Ovarian cancer drug delivers ‘very promsing’ results in early trial
June 3, 2017: “Researchers believe the drug, which mimics the action of folic acid to enter cells, could hold huge promise for women with advanced ovarian cancer who have stopped responding to standard treatment.” Read more.
ASCO: Does chemotherapy in breast and ovarian cancer patients cause AML and MDS?
June 3, 2017: New data presented at ASCO 2017 shows “that the incidence of MDS and AML in ovarian and breast cancer patients was higher in patients exposed to DNA damaging agents.” Read more.
Promising activity reported for nivolumab in gynecologic cancers
June 03, 2017: From Cancer Therapy Advisor’s coverage of the 2017 ASCO meeting: “Nivolumab, a programmed death (PD)-1 inhibitor, showed promising clinical activity in recurrent or metastatic cervical cancers and provides a promising new approach to treatment, according to data from the CheckMate 358 trial.” Read more.
Lynparza (olaparib) maintenance treatment offers sustained quality of life alongside improved progression-free survival in women with BRCA-mutated ovarian cancer
June 2, 2017: Business wire: “AstraZeneca today reported new data from the Phase III SOLO-2 trial of Lynparza (olaparib) 300mg twice-daily tablet maintenance treatment showing that quality of life (QoL) is sustained alongside improved progression-free survival (PFS) in women with germline BRCA-mutated (gBRCAm), platinum-sensitive, relapsed serous ovarian cancer.” Read more.
Dr. Wingo on gynecologic oncology guidelines
June 1, 2017: From OncLive, Dr. Shana Wingo discusses the guidelines publsied in JCO and Gynecologic Oncology recommending all patients with gynecologic malignancies be referred to a gynecologic oncologist. Watch the video.
HIV may prompt progression of HPV infection to cervical pre-cancer
June 1, 2017: From Healio: “HPV infection appeared more likely to progress to cervical precancer in women with HIV, according to an analysis from multiple cohorts in Senegal, West Africa.” Read more.
Breastfeeding linked to lower endometrial cancer risk
June 1, 2017: Reuters Health reports: “In the analysis of data from 17 past studies, researchers found that women who had ever breastfed their children were 11 percent less likely than women who had children but didn’t breastfeed to be diagnosed with endometrial cancer.” Read more.
New tech promises easier cervical cancer screening
May 31, 2017: Science Daily reports: “Researchers have developed a handheld device for cervical cancer screening that promises to do away with uncomfortable speculums and high-cost colposcopes. If widely adopted, women might even self-screen, transforming screening and cure rates in low-income regions where cervical cancer is most prevalent.” Read more.
Bariatric surgery linked to lower risk of female-specific cancers
May 31, 2017: Published in Gynecologic Oncology, “a new study finds that bariatric surgery can have beneficial effects for women beyond just weight loss: it was also associated with lower risk of female-specific cancers, like breast or ovarian cancer.” Read more.
Unexpected presence of glucose receptor in ovarian cancer links metabolism to most aggressive cases
May 30, 2017: Science Daily reports: “A new study of non-diabetic women with ovarian cancer reveals a potential correlation and area for further study regarding the expression of the GLUT1 glucose transporter receptor at the cancer tissue level. GLUT1 is a receptor protein involved in the absorption of glucose, or sugar, in the bloodstream and across membranes in the body.” Read more.
HPV cancer risk remains high after CIN3 Dx
May 30, 2017: Med Page Today reports: “The increased risk for HPV-related carcinomas and pre-malignancies of the anogenital and oropharyngeal region can last for decades after a diagnosis of cervical intra-epithelial neoplasia grade 3 (CIN3), leaving previously diagnosed older and unvaccinated women at significant risk, according to researchers.” Read more.
Open-access genetic screening for hereditary breast cancer is feasible, effective
May 27, 2017: From Science Daily: “Offering open-access genetic testing for the inherited breast cancers BRCA1 and 2 to Ashkenazi women unaffected by cancer, regardless of their family history, enables the identification of carriers who would otherwise have been missed, a new study demonstrates.” Read more.
New cellular target may put the brakes on cancer’s ability to spread
May 26, 2017: From Science Daily: “Researchers have discovered a biochemical signaling process that causes densely packed cancer cells to break away from a tumor and spread the disease elsewhere in the body.” Read more.
New guidance for targeting residual ovarian tumors
May 23, 2017: from Science Daily: “Researchers who are working on an implantable device that could make intraperitoneal chemotherapy more bearable have published a new study that offers insight into how to improve chemotherapy strategies for ovarian cancer, and how to determine which patients would be most likely to benefit from their device.” Read more.
In landmark move, FDA approves cancer drug for a biomarker, not a tissue
May 23, 2017: MedCity News reports FDA approval of Merck’s checkpoint inhibitor, Keytruda (pembrolizumab), for patients with solid tumors that express so-called mismatched repair genes. This approval marks a change in the precision medicine industry. Read more.
US doctors trained in Shanghai
May 23, 2017: Article from ShanghaiDaily.com notes that a team of doctors from Northwestern University spent two weeks at the Shanghai Tumor Center training for cervical cancer surgery. Read the article.
Early Diagnosis of gynecologic cancers in ladies with review of literature
May 2017: Literature review published in the Open Journal of Obstetrics and Gynecology discussing the importance of tumor markers for early diagnosis of gynecological malignancies. Read the review.
Gynecologic oncology and colposcopy clinic opens in Hamad, Qatar
May 22, 2017: Hamad Medical Corporation’s Women’s Wellness and Research Center is now welcoming gynecologic oncology patient’s to its clinic. Read more about the clinic including a brief interview with Dr. Jonathan Herod.
National survey shows resource, emotional and support needs of the ovarian cancer community
May 22, 2017: TESARO announces results of a national survey of patients and healthcare providers to understand education and support needs of advanced ovarian cancer patients. “Created with input from leading ovarian cancer advocacy groups – National Ovarian Cancer Coalition (NOCC) and Ovarian Cancer Research Fund Alliance (OCRFA) – the results from the survey indicate that regardless of the stage of ovarian cancer, there is uncertainty among patients about what to expect after diagnosis – whether they are initially diagnosed or actively seeking greater resources and connections to lessen the burden of the disease.” Read more.
Impact of prophylactic HPV vaccination on oral HPV infections among young adults in the US
May 20, 2017: Abstract to be presented at the 2017 ASCO Meeting finds that the “HPV vaccination substantially reduced vaccine-type oral HPV infection prevalence among young adults (ages 18-33 years) in the US population during 2011-2014. However, due to low vaccine uptake, population-level effectiveness was modest overall and particularly low in men.” Read the abstract.
Avastin benefit varies by ovarian cancer subtype
May 19, 2017: Cure Today reports on a recent study finding Avastin to be more effective in treating certain types of ovarian cancer. Brian Slomovitz, MD (USA) weighs in on a study by Stefan Kommoss, MD (Germany). Read more.
Is artificial intelligence the future of cervical cancer detection?
May 19, 2017: “After a decade of work, scientists from Lehigh University have created a cervical cancer screening technique that has the potential to outperform humans at a significantly lower cost. The investigators believe the technique could be used in developing countries, and are currently seeking funding to conduct clinical trials using the data-drive method.” Read more.
Women opt to skip pelvic exams when told they have little benefit
May 18, 2017: NPR discusses the difference of recommendations between ACOG and the American College of Physicians regarding frequency of pelvic examination. Read the article.
Deficiencies in repair of DNA identified in many types of solid tumors
May 17, 2017: “A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.” Read the article.
Ovarian cancer patient actively seeking PARP inhibitor therapy, expert says
May 15, 2017: Dr. Dennis Scribner interviewed by Targeted Oncology discusses treatment options for patients with recurrent ovarian cancer, including how PARP inhibitors have enhanced these options. Read the interview.
Why burnout is so hard to fix
May 11, 2017: Editorial in the Journal of Oncology Practice discusses the insidious onset of burnout, beginning with the clinicians desire to prove their worth and the trajectory that follows. A must read for hard working clinicians. (log-in required)
11 Subtle signs of ovarian cancer & when you should see a doctor
May 10, 2017: Several gynecologic oncologists weigh in on this comprehensive list of early warning signs of ovarian cancer. Read and share the list.
Editorial: Finding the rare pathogenic variants in a human genome
May 9, 2017: JAMA Insights – Genomics and Precision Health published an editorial with the abstract, “Decreases in the cost of DNA sequencing have enabled substantial progress in fields ranging from archaeology and evolution to basic biomedical science. Concomitantly, there have been calls for routine genome-scale sequencing of healthy individuals in hopes of discovering clinically important information. For example, discovery of a high risk of breast and ovarian cancer due to a BRCA1/2 mutation can enable aggressive surveillance or risk-reducing surgery.” Read more.
Vaccine reduces HPV prevalence in teens, young adults
May 9, 2017: Medpage today reports the prevalence of HPV has fallen among young women in the U.S. since vaccination was recommended in 2006; first evidence that herd immunity protects unvaccinated individuals. Read the article.
Cancer antigen expression associated with prognosis in ovarian cancer
May 3, 2017: “Patients with ovarian cancer who express the NY-ESO-1 testis antigen have significantly shorter overall survival than those who do not, according to a new study. These patients may benefit from immunotherapy agents.” Read more from Cancer Network.
Expert discusses excitement for immunotherapy potential in ovarian cancer
May 2, 2017: “Results of the phase III JAVELIN 200 Ovarian trial have the potential to make a practice-changing impact on the field of ovarian cancer, according to Bradley J. Monk, MD, as immunotherapy could finally make its mark on management of this disease.” Read the full article from Targeted Oncology.
Combination therapy may be effective option for treating some women with ovarian cancer
May 2, 2017: “Dr. Sanaz Memarzadeh’s research, published in the journal Precision Oncology, shows a new combination therapy of carboplatin and an experimental drug called birinapant can improve survival in mice with ovarian cancer tumors. Additional findings reveal that testing for a specific protein could identify ovarian tumors for which the treatment could be effective.” Read more.
PET/CT can evaluate lymph node metastasis in high-risk endometrial cancer
April 28, 2017: Diagnostic Imaging reports “Adding fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) to CT allows for better detection of lymph node (LN) metastasis in high-risk endometrial cancer, according to a study published in the journal Radiology.” Read more.
Rucaparib leads to frequent durable remissions in BRCA-mutated relapsed ovarian cancer
April 25, 2017: Reported by ASCO Post: “Rucaparib (Rubraca) led to frequent durable remissions among patients with relapsed high-grade ovarian cancer with BRCA mutations, regardless of whether the mutations were germline or somatic, according to the results of the ARIEL2 trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting.” Read more.
Therapeutic vaccine designed to reduce recurrence of cervical cancer under study
April 25, 2017: Eureka Alert reports “The vaccine is being studied in patients at high risk because of evidence that cancer cells have spread to lymph nodes in their pelvis or because their disease was diagnosed in the later stages the first time. It’s believed to evoke an immune response that enables the woman’s own body to better stave off the disease.” Read the article including an interview with Dr. Sharad A. Ghamande (USA).
Genomic consequences of abberant DNA repair mechanisms stratify ovarian cancer histotypes
April 24, 2017: Article published in Nature Genetics “establishes the potency of the somatic genome, reflective of diverse DNA repair deficiencies, to stratify ovarian cancers into distinct biological strata within the major histotypes.” Read the abstract.
Adding bevacizumab to chemo may prolong survival in recurrent ovarian cancer
April 24, 2017: Cancer Therapy Adviser reports the results of a study published in Lancet Oncology – According to the authors, the results of this study suggest that “bevacizumab added to paclitaxel and carboplatin might favourably affect overall survival in women with platinum-sensitive recurrent ovarian cancer.” Read more.
Recruitment begins for world’s first ovarian cancer vaccine
April 20, 2017: Medical Xpress reports that “UConn Health is beginning to recruit patients for the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. The goal: to prevent an often deadly relapse of the disease in women diagnosed at advanced stages.” Read more.
Hypertension linked to better outcomes for subset of ovarian cancer patients
April 17, 2017: “New research from epidemiologists at Roswell Park Cancer Institute, published in the journal Cancer Causes & Control, provides evidence that hypertension and diabetes and the use of medications to treat these common conditions may influence the survival of ovarian cancer patients; sometimes in a detrimental way, but in the case of hypertension medications, perhaps as a benefit.” Read the article from News Medical Net.
PARP inhibitors: the cornerstone of DNA repair-targeted therapies
April 15, 2017: Cancer Network posted a comprehensive review article on DNA repair and the role of PARP. Read the full article.
When early-stage vulvar cancer recurs, the prognosis is poor
March 30, 2017: Watch this video interview with Dr. Rebecca Stone regarding the retrospective, multi-institutional cohort study examining stage IB vulvar cancer
How to start an oncology sexual health clinic
March 30, 2017: Watch this video interview with Joanne Rash, PA-C regarding a successful model to integrate sexual health into cancer care.
Non-Drug therapies found best for managing cancer fatigue
March 29, 2017: Behavioral therapies were significantly better than drugs for improving cancer-related fatigue during and after treatment, and should be prescribed as first-line treatments, according to a meta-analysis. Read more.
Vermillion announces publication of ovarian cancer symptoms index study
March 29, 2017: The original research titled, “Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy,” by Renata R. Urban, MD, Alan Smith, MS, Kathy Agnew, Vinicius Bonato, PhD, and Barbara A. Goff, MD, was acceptend for publication in the International Journal of Gynecological Cancer. Read the press release.
FDA grants Lynparza priority review for maintenance treatment of ovarian cancer
March 28, 2017: The new drug application for olaparib includes data from the phase III SOLO-2 trial presented at the SGO Annual Meeting. The FDA is expected to make a decision on this drug by the third quarter of 2017. Read more.
Promoting minimally invasive surgery for endometrial CA ‘should be a priority’
March 28, 2017: “The phase III Laparoscopic Approach to Cancer of the Endometrium (LACE) trial in women with stage I endometrial cancer showed nearly identical rates of disease-free survival at 4.5 years with total laparoscopic hysterectomy (TLH) versus total abdominal hysterectomy (TAH) (81.3% versus 81.6%, respectively, P=0.007), meeting prespecified criteria for equivalence.” MedPage Today interviews Dr. Andreas Obermair and Dr. Jason Wright. Read more.
Parental self-persuasion in low-income groups improves HPV vaccination rates
March 28, 2017: Study guides parents to consider why HPV vaccination is important and explain it’s benefit in their own words. See more.
FDA approves Zejula for maintenance treatment of gynecologic cancers
March 27, 2017: The FDA approved niraparib for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers who achieved complete or partial response to platinum-based chemotherapy. Read more.
Ten years on, Professor Ian Frazer recalls ‘lucky’ discovery of cervical cancer vaccine
March 25, 2017: Professor Frazer recently spoke at the World Science Festival in Brisbane, Australia and was interviewed regarding his team’s discovery of the cervical cancer vaccine. Read the highlights from the interview.
Adjuvant and systemic therapy for rare tumors of the uterus and cervix
March 25, 2017: HemOnc Today offers practical advice on the treatment of rare diseases of the uterus and cervix by summarizing the latest research in a commentary written by Drs. Erin Crane, Jubilee Brown and Wendel Naumann. Read the commentary.
What all women need to know about gynecologic cancers
March 24, 2017: Health reporter Diane Atwood writes about her friend’s experience with stage III fallopian tube cancer and interviews gynecologic oncologist, Dr. Emmanuel Soultanakis, providing a complete summary of signs, symptoms and risk factors for gynecologic cancers. Read the blog.
Cancer survivors more likely to have preterm birth, cesarean delivery
March 23, 2017: Dr. Hazel B. Nichols is interviewed by HemOnc Today regarding her research that suggests women treated with chemotherapy may have increased risk for preterm birth in the future. Read the interview.
Combination yields ‘promising’ results for recurrent, BRCA-deficient ovarian cancer
March 23, 2017: An interview with Dr. Sarah Adams (University of New Mexico) regarding the phase 2 clinical trial studying combination treatment of olaparib (lynparza, AstraZeneca) and tremellimumab. Read the interview.
A call for molecular profiling in uterine carcinosarcoma
March 22, 2017: OncLive interviews Dr. Douglas Levine regarding the recent published paper in Cancer Cell, which charted the biology of 57 patients with uterine carcinosarcoma. Dr. Levine states that the “results really call for molecular profiling of this rare-type of tumor.” Read the interview.
Implementation of cervical cancer screening in developing countries
March 21, 2017: OncLive interviews Dr. Ann Marie Beddoe regarding her study implementing cervical cancer screening in Limpopo, South Africa. Read the interview.
Research into talcum powder – ovarian cancer link reveals troubling differences based on study designs
March 21, 2017: HemOnc Today interviews Dr. Paolo Boffeta regarding his team’s systematic review and meta-analysis evaluating the association between genital talcum powder use and ovarian cancer risk. Boffeta says that evidence falls short from demonstrating a casual link. Read the interview.
Hormonal maintenance therapy prolongs PFS for serous carcinoma of ovary, peritoneum
March 20, 2017: HemOnc Today interviews Dr. David Gershenson regarding the findings of a retrospective study that show “women with stage II to stage IV low-grade serous carcinoma of the ovary or peritoneum demonstrated longer PFS when treated with hormonal maintenance therapy after primary chemotherapy rather than routine observation.” Read the interview.
Hamad Medical Center holds first Qatar gynecologic malignancy symposium
March 20, 2017: The symposium addressed important issues in women’s cancer with a focus on the development of collaborative research and training in the GCC and MENA region. Read the press release.
Oral apixaban safe for thromboprophylaxis before surgery in gynecologic cancers
March 17, 2017: Presented at SGO 2017 by Dr. Saketh Guntupalli, “Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies. The oral medication may provide an option that would increase compliance and satisfaction in this setting.” Read the CancerNetwork article.
Readmission rates after gynecologic surgery may not be a valid measurement of quality care
March 16, 2017: Two studies presented at SGO 2017 indicate “Surgeons should focus on long-term outcomes for the treatment of ovarian cancer rather than hospital readmission rates after surgery.” Read the Healio.com article.
Priority symptoms identified in recurrent ovarian cancer
March 16, 2017: Presented at SGO 2017, the National Cancer Institute and National Academy of Sciences have identified 18 core symptoms that should be assessed among patients with recurrent OC. Read this news article to learn the symptoms.
Immunotherapy AXAL tops survival mark in cervical cancer
March 15, 2017: OncLive interviews Dr. Charles Leath III regarding immunotherapy, AXAL which targets HPV-infected cells. The phase II study led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer. Read the interview.
Immunotherapy motolimod fails to improve survival in ovarian cancer
March 15, 2017: Data presented by Dr. Bradley Monk at SGO 2017: “The addition of the immune therapy motolimod to pegylated liposomal doxorubicin (PLD) failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial. There was a survival advantage, however, specifically in patients who experienced injection site reactions, which could help guide the use of this therapy.” Read the CancerNetwork article.
Sentinel lymph node mapping cost-effective in endometrial carcinoma
March 15, 2017: “Sentinel lymph node (SLN) mapping is cost-effective compared with other methods of lymphadenectomy (LND) in the management of low-risk endometrial carcinoma, according to a decision analysis model study presented at the 2017 SGO Annual Meeting.” Read more.
Integrated molecular characterization of uterine carcinosarcoma
March 2017: This integrated genomic and proteomic analysis of 57 uterine carcinosarcomas provides insights into disease biology and offers therapeutic opportunities. Read the full text.
Advaxis presents oral late-breaking data on phase II GOG-0265 study of Axalimogene Filolisbac
March 15, 2017: Data presented at the 2017 SGO Annual Meeting: “Unprecedented 12-month survival rate for metastatic cervical cancer observed” Read the press release. Read the Medpage Today story on the same study.
Gene expression signature predicts outcomes in endometrial cancer
March 14, 2017: “A 7-transcript classifiers (MS7) effectively predicted metastatic disease for patients with endometrioid endometrial cancer (EEC), with added promise shown when the gene expression signature was combined with pathologic features, according to findings presented at the 2017 SGO Meeting.” Read more.
MMR deficiency linked to PD-L1 expression in endometrial cancer
March 14, 2017: “Mismatch repair (MMR)–deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors, according to a poster presentation at the 2017 SGO Annual Meeting.” Read more.
Reduction strategies improve surgical site infection rate after colon surgery
March 14, 2017: “Introduction of a surgical site infection (SSI) reduction bundle significantly improved 30-day SSI rates among gynecologic cancer patients undergoing colon surgery, according to a study presented at the 2017 SGO Annual Meeting.” Read more.
Niraparib maintenance results have paradigm-shifting potential in ovarian cancer
March 14, 2017: Targeted Oncology interviewed Dr. Kathleen Moore and Dr. Ursula Matulonis at the 2017 SGO Annual Meeting, discussing the use of PARP inhibitors such as niraparib for the treatment of ovarian cancer – advances that could be practice changing. Read the interview with Dr. Moore. Read the interview with Dr. Matulonis.
Carboplatin desensitation leads to improved OS in ovarian cancer
March 14, 2017: Patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen had an improved overall survival (OS), according to a retrospective analysis reported at the 2017 SGO Annual Meeting on Women’s Cancer.” Read more.
Maintenance chemo after CR fails to extend survival in ovarian cancer
March 14, 2017: Presented at the 2017 SGO Annual Meeting on Women’s Cancer: “A long-term phase III randomized trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response (CR) to first-line therapy. Maintenance chemotherapy also increased toxicity in these patients.” Read more.
LYNPARZA™ (olaparib) phase III SOLO-2 data demonstrated progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy
March 14, 2017: AstraZeneca shares results of Phase III trial: “The SOLO-2 data demonstrated a statistically significant and clinically meaningful improvement in outcomes for those who took olaparib. The results, which showed a delay in disease progression in the maintenance setting, highlight the impact of PARP inhibition at the forefront of the important advances we are making in targeting ovarian cancer.” Read the full press release. Read the Healio.com story. Read the MedPage Today story.
Enhanced Recovery after surgery for ovarian cancer patients
March 14, 2017: A cancernetwork.com interview with Dr. Robert Neff regarding his data presented at the 2017 SGO Annual Meeting on Women’s Cancer that compared the cost-effectiveness of an enhanced recovery program compared with usual care following patients who had surgical cytoreduction for their ovarian cancer. Read or listen to the interview.
Parents continue to see HPV vaccine as unnecessary and worry over its safety
March 13, 2017: In an effort to understand the relatively low uptake of the human papillomavirus (HPV) vaccine in the United States, a survey of parents of teenage girls has found that a lack of knowledge about the vaccine and a failure by healthcare providers to recommend it, superseded parental concern about their daughters’ not needing it because they are not sexually active. Read more about the survey results.
Three doses of HPV vaccine no more beneficial than two
March 13, 2017: Presented at SGO 2017, investigators observed no significant difference in outcomes between patients who received 2 doses of the vaccine and those who received 3 doses. Read the article.
Gynecologic Oncologists cite time, money as barriers to global health participation
March 12, 2017: “Lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists’ participation in global health activities, according to a study reported at the Society of Gynecologic Oncology (SGO) in National Harbor, MD.” Read more.
Research shows vitamin B3 reduces pain from chemotherapy induced peripheral neuropathy
March 10, 2017: “Rats given prophylactic daily doses of nicotinamide riboside at 200 mg/kg 7 days prior to chemotherapy and continuing for 24 days after the termination of chemotherapy did not experience peripheral nerve hypersensitivity.” Read more.
Reversion mutations may predict chemotherapy response in recurrent serous ovarian cancer
March 7, 2017: “The detection of reversion BRCA1 or BRCA2 mutations among women with recurrent high-grade serous ovarian cancer predicted response to chemotherapy treatment, according to study results.” Read more.
Study shows platelets can deliver immunotherapy, reduce tumor regrowth
March 3, 2017: A new NCI study suggests that blood platelets engineered to deliver an immunotherapy drug may effectively eliminate cancer cells missed by surgery and prevent them from forming new tumors. Read the NCI blog.
Ovarian cancer target molecule may be key to blocking its spread
March 2, 2017: “Blocking a protein found on the surface of ovarian cancer cells could prevent or reduce the spread of the disease to other organs, according to new research.” Read more.
The Pap smear: groundbreaking, lifesaving – and obsolete?
March 1, 2017: With new ways to collect data, including HPV testing, is the Pap past it’s prime? Read more.
Lowering GI Toxicities in Gynecologic Cancers
March 1, 2017: “Intensity-modulated radiation therapy (IMRT) proved to lower the incidence of gastrointestinal toxicities in patients with gynecologic malignancies, according to the results from a recent study.” Read more.
NEJM: The changing face of clinical trials
March 2017: A collection of articles that examine the current challenges in the design, performance, and interpretation of clinical trials. Read the collection.
Controlled interventions to reduce burnout in physicians: a systematic review and meta-analysis
February 2017: This meta-analysis of 20 controlled interventions on 1550 physicians found that existing interventions were associated with small and significant reductions in burnout. The strongest evidence for effectiveness was found for organization-directed interventions, but these interventions were rare. Read more.
Special issue in Clinical Oncology: Radiotherapy in low and middle income countries
February 2017: the Feb. special issue of Clinical Oncology includes an editorial and several studies and analysis of radiotherapy in low and middle income countries. See the issue.
Ovarian cancer screening has some benefits in high-risk women
February 28, 2017: “Screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the 1 year after screening ended, a multicenter study showed.” Read more.
Evolution of surgical management optimizes care for patients with rare gynecologic tumors
February 25, 2017: This commentary reiterates that “significant progress has been made in the treatment of rare gynecologic cancers over the past decade, and clinicians should be aware of these advances in order to provide optimal patient care.” Read more.
Low recurrence after risk-reducing surgery for BRCA carriers
February 24, 2017: Dr. Maurie Markman discusses a paper that appeared in the journal Gynecologic Oncology, entitled “Occult and Subsequent Cancer Incidence Following the Risk-Reducing Surgery in BRCA Mutation Carriers.” Read more.
Researcher finds safer, less invasive method of staging endometrial cancer
February 24, 2017: “Emma Rossi, MD, in the UNC Department of Obstetric and Gynecology’s Division of Gynecologic Oncology, has published a study in Lancet Oncology online that identifies sentinel-lymph-node mapping as a safer and less-invasive method of staging endometrial cancer that is equally as accurate as the more traditional lymphadenectomy.” Read more.
Researchers use genetics to identify cancer recurrence risk
February 22, 2017: University of Wisconsin-Madison researcher, Christine Kendziorski and her team of researchers have identified a set of genetic traits that indicate a person may have a relapse of ovarian cancer. Read more.
Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer
February 21, 2017: For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. Read more.
Two studies bring bad news about cervical cancer deaths and HPV – So what can we do?
February 17, 2017: The importance of screening and vaccination – and less stigma. Read more.
LEEP rather than freeze to prevent cervical cancer
February 15, 2017: “HIV-infected women who develop high-risk cervical lesions and undergo loop electrosurgical excisional procedures (LEEP) had less risk of recurrence or of cervical cancer than similar women in resource-poor settings treated with cryotherapy.” Read more.
Analyzing copies of genes may offer new therapeutic approaches for ovarian cancer
February 15, 2017: “A team of 18 University of California San Diego School of Medicine and Moores Cancer Center researchers has developed a new tool to analyze an often overlooked aspect of cancer genetics — an alteration that results in the loss or gain in a copy of a gene. This change, known as somatic copy-number alterations, may be key to disease progression and might offer new therapeutic approaches for ovarian cancer and other malignancies.” Read more.
Study links ovarian cancer growth to gene defects
February 14, 2017: Defects in a key gene—long thought to drive cancer by turning off the protection afforded by the BRCA genes—spur cancer growth on their own, according to a study led by researchers from NYU Langone Medical Center The study gene, known as EMSY, has some of the same functions as BRCA1 and BRCA2 and helps explain why some women with healthy BRCA1 and BRCA2 genes develop cancer. Read more.
BRCA reversion mutations in cfDNA can predict response in ovarian cancer
February 14, 2017: A small study found that it is feasible to detect BRCA1/2 reversion mutations in circulating cell-free DNA (cfDNA) in patients with recurrent high-grade serous ovarian cancer (HGSC). Those reversion mutations can help predict poor response to therapy in these patients. Read more.
Mayo Clinic program examines ovarian cancer applications for liquid biopsy
February 10, 2017: “The goal of the Ovarian Cancer Project is to identify biomarkers that can be used to treat ovarian cancers that have not responded to conventional treatments such as debulking and chemotherapy. By customizing treatment, interventions may be more effective at achieving a cure. In addition, the program is working to identify biomarkers that can be used to follow patients over time, allowing early identification of ovarian cancer recurrence.” Read more.
Retroperitoneal exploration improves survival in optimally debulked advanced epithelial ovarian cancer.
February 6, 2017: “Retroperitoneal exploration at the time of primary debulking surgery appeared to improve survival in patients with intraperitoneal stage IIIC optimally debulked epithelial ovarian cancer, according to data collected from a large multi-institutional trial.” Read more.
Dr. Levine on combos with PARP inhibitors in ovarian cancer
February 3, 2017: Dr. Douglas Levine on OncLive discusses combining PARP inhibitors with chemotherapy as well as the question of when and how to give them. View the video.
Diagnostic laparascopies can prevent future surgeries in ovarian cancer
February 1, 2017: A study published in the Journal of Clinical Oncology shows that “the number of futile laparotomies was decreased in patients with advanced stage ovarian cancer who underwent diagnostic laparoscopies.” Read more.
Homologous recombination deficiency analysis predicts PARP inhibitor benefit for ovarian cancer
January 27, 2017: “Next-generation sequencing used to detect homologous recombination deficiency may predict responses to rucaparib in patients with BRCA wild-type platinum-sensitive ovarian cancers, according to results from the international, multicenter, open-label phase 2 trial ARIEL2 study.” Read more.
Lynch syndrome – associated ovarian cancer presents early, has good prognosis
January 25, 2017: An analysis of Lynch syndrome–associated ovarian cancer published in Gynecologic Oncology found that the malignancy tends to present at an early stage and has a generally good prognosis. Ovarian surveillance may be useful in some women to detect this malignancy early. Read more.
Murine study finds potential boost for ovarian cancer drug Olaparib
January 25, 2017: “Researchers have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings suggest that this FDA-approved ovarian cancer medicine has the potential to treat a wider range of cancer types than currently indicated.” Read more about this study.
TCGA study identifies genomic features of cervical cancer
January 24, 2017: A news release from the National Institutes of Health announces “investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in the subclassification of the disease and may help target therapies that are most appropriate for each patient.” Read more.
Study pinpoints opportunity for oncologists to improve communication with patients.
January 24, 2017: A study published in the Journal of Oncology Practice looked at doctor-patient conversations and found that doctors naturally avoid difficult discussions about a challenging prognosis. This shows there may be missed opportunities to discuss what test results actually mean and allow the patient and family members to process and explore the situation. Read more.
Cervical cancer deaths rates are much higher than previously thought
January 23, 2017: “Black women are dying from cervical cancer at a rate 77% higher than previously thought, and white women are dying at a rate 47% higher, according to a study published in the journal Cancer. The study found that previous estimates of cervical cancer death rates didn’t account for women who had their cervixes removed in hysterectomy procedures, which eliminates the risk of developing the cancer.” Read more.
Endometrioid ovarian cancer presents earlier, offers better survival than serous carcinoma
January 20, 2017: “Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.” Read more.
Countries with limited health care resources need education regarding breast cancer risk factors
January, 2017: Survey reveals there is a need for breast cancer education in limited resource countries. Read more.
Ovarian conservation may boost outcomes in endometrial cancer
January 18, 2017: MedPage Today (free login required) writes, “Ovarian conservation was associated with decreased long-term all-cause mortality in young women with low-grade, early-stage endometrial cancer,, according to researchers.” Read more.
Why are we still talking about ‘ovarian’ cancer?
January 18, 2017: Seventy-five percent of the most deadly ‘ovarian’ cancer arises in the fallopian tubes. Should the new name for ovarian cancer be pelvic serous carcinoma? Read more.
More Chemo may not equal better outcomes in ovarian cancer
January 16, 2017: MedPage Today (free login required) writes “Increasing, the number of cycles of chemotherapy doesn’t appear to significantly influence recurrence rates or survival in patients with early stage ovarian clear cell carcinoma (OCCC), according to researchers.” Read more.
Assessment identifies patients with endometrial cancer at low risk for lymph node metastasis
January 13, 2017: “Preoperative assessment of lymph node metastasis in endometrial cancer may encourage selective lymphadenectomy for low-risk patients,” according to a study by Dr. Sokbom Kang and colleagues at the Research Institute and Hospital of National Cancer Center in the Republic of Korea. Read more.
Research evaluates treatment options for pelvic organ prolapse
January 12, 2017: Recently published in the American Journal of Obstetrics & Gynecology, research “found that while women undergoing surgery or having a pessary achieve their goals and have improvements in physical, social and emotional functioning, those who underwent surgery experienced greater improvements.” Read more.
Researchers discover new subtype of cervical cancer
January 10, 2017: “A team of University of South Carolina scientists led by Carolyn Banister and Phillip Buckhaults has identified a new subtype of cervical cancer that, like most cervical cancers, is triggered by human papillomavirus (HPV) but whose growth is not directed by the virus, suggesting that therapy targeting these tumors’ distinct genomic pathways may improve patient outcomes over standard treatment.” Read more.
Bush Institute’s recommendations on global health policy
January 10, 2017: The George W. Bush Institute recommends that the US continue to invest in global health initiatives such as HIV and AIDS prevention and treatment and focusing on women’s healthcare. Read more.
Diagnostic laparoscopy to reduce the likelihood of futile laparotomy
January 10, 2017: “Treatment with diagnostic laparoscopy rather than primary surgery may lower the rate of futile laparotomies among women with suspected advanced ovarian cancer according to a study published in the Journal of Clinical Oncology.” Read more.
New clinical trial combines two methods to defeat ovarian cancer
January 9, 2017: A new clinical trial at the University of New Mexico is testing a new approach to defeat ovarian cancer. “The clinical trial treats women whose ovarian cancer results from mutated BRCA genes. It uses one drug that kills the ovarian cancer cells and another that boosts the immune system in response to the dying cancer cells.” Read more.
ASCO updates clinical guideline to include palliative care
January 9, 2017: The key recommendation is that “Patients with advanced cancer, whether inpatient or outpatient, should receive dedicated palliative care services, early in the disease course, concurrent with active treatment.” Read more.
Study shows that BRCA status does not affect survival outcomes in young women with early breast cancer
December 25, 2016: “The study showed that patients with BRCA-positive breast cancer may safely delay bilateral mastectomy, since an immediate bilateral mastectomy within the first year of diagnosis did not affect survival.” Read more.
Endometrial cancer mutations are detectable in uterine lavage fluid before cancer is diagnosed
December 29, 2016: A press release from Newswise highlighted the findings of a study published in PLOS Medicine, “Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.” Read the article.
CT-planned, high-dose-rate brachytherapy effective in cervical cancer
December 28, 2016: OncLive posted an article summarizing the results of a recent study published in Gynecologic Oncology. Lead author, Akila Viswanathan, MD, Executive Vice Chair, Johns Hopkins Radiation Oncology and Molecular Radiation Sciences wrote in the study: “We found that, of 9 patient characteristics and various RT prognostic factors tested in a univariate analysis, tumor size and total external beam radiation therapy (EBRT) plus BT dose were initially the most significant prognostic factors for predicting any recurrence (AR)” Read the full article.
Combination of Camptosar and Avastin safe and effective for recurrent ovarian cancer
December 27, 2016: MedPage Today reported the findings of a phase II study in the journal Gynecologic Oncology demonstrating that Camptosar and Avastin “may be a safe and effective alternative in heavily pre-treated patients with recurrent ovarian cancer, including those with prior bevacizumab and topoisomerase inhibitor use.” Read the full article.
FDA grants priority review of TESARO’s niraparib for gynecologic cancers
December 21, 2016: “The FDA granted priority review to niraparib for the treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer following response to platinum-based chemotherapy.” Read more.
Fallopian tubes may have big role to play in ovarian cancer fight
December 20, 2016: CNN posted an article noting that “research increasingly points to the likelihood that some of the most aggressive ovarian cancers originate in the fallopian tubes.” Read more.
FDA grants accelerated approval to rucaparib to treat certain types of ovarian cancer
December 19, 2016: The U.S. Food and Drug Administration granted accelerated approval to Rubraca (rucaparib) to treat “women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified be an FDA-approved companion diagnostic test.” Read the press release. Watch this brief video of Dr. Michael Birrer discussing the treatment.
Leading cause of cancer mortality in the Caribbean region from 2003-2013
December 16, 2016: The Centers for Disease Control and Prevention (CDC) released a report stating the cancer is the second leading cause of mortality in the Caribbean region. “Among females, breast cancer was the most common cause of cancer deaths in 16 of the 18 countries for which data were reported, accounting for 14.0%–29.7% of cancer deaths, followed by cervical cancer, which accounted for 4.5%–18.2% of cancer deaths.” Read the full report.
Early surgery may increase risk of death for some uterine cancer patients
December 16, 2016: MedicalXpress.com published an article referencing a new study in the American Journal of Obstetrics and Gynecology. “In the study, women who had surgery (usually to remove the uterus) within the first two weeks after diagnosis had a significantly increased risk of death within five years, compared to those who had surgery three or four weeks after their initial diagnosis.” Read the full article.
Biomarkers are a top priority in immunotherapy progress in ovarian cancer
December 13, 2016: OncLive published an article interviewing Dr. Maurie Markman regarding the importance of searching for “validated, actionable biomarkers” which “may lead to accelerated approval of…drugs, because of very high response rates in those selected populations.” Read the full interview.
FDA approves Genentech’s Avastin (Bevacizumab) plus chemotherapy for a specific type of advanced ovarian cancer
December 6, 2016: The press release notes “Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone.” Read the press release.
JAMA publishes a systematic analysis of the global burden of disease
December 3, 2016: The analysis provides global, regional and national cancer incidence and more for 32 cancer groups, including cervical, uterine and ovarian cancer from 1990-2015. The study reports that in 2015, 526,000 women developed cervical cancer worldwide, causing 239,000 deaths. In low service delivery indicator (SDI) countries, 1 in 24 women developed cervical cancer while in high SDI countries 1 in 115 women developed cervical cancer during a lifetime. Read the full analysis.
New York Times publishes article “What Not to Say to a Cancer Patient”
November 28, 2016: The New York times promotes the book “Loving, Supporting, and Caring for the Cancer Patient” which provides helpful suggestions to the friends and family members of cancer patients. Read the article.
JCO study on neoadjuvant chemotherapy
November, 2016: The Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO) published a study on the use and effectiveness of neoadjuvant chemotherapy for the treatment of ovarian cancer. The findings of the study “suggest that in carefully selected patients with stage IIIC disease, PCS is associated with a survival advantage, with overall low rates of surgical morbidity. In contrast, for patients with stage IV disease, … results confirm that NACT is noninferior to PCS for survival, with fewer ICU admissions and rehospitalizations, which suggests that NACT may be preferable for patients with stage IV ovarian cancer.” Read the full JCO study.